This is a working overview of synaptogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-25. Anything still debated is marked as such rather than presented as settled.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Saudi Arabia: Saudi Arabia expressed its strong support for the actions taken by the Syrian government in order to attain territorial integrity, called on the international community to stand with Syria and condemned the Israeli airstrikes. Turkey: Turkey expressed its support for the actions taken by Syria to assure its territorial integrity and condemned the Israeli intervention in the conflict. United Kingdom: A British envoy to Syria calls for de-escalation in the south of the country. Syrian Ministry of Foreign Affairs and Expatriates: stated that condemnations of Israeli attacks on Syria were also expressed by Afghanistan, Denmark, Greece, Norway, Pakistan, Panama, Sierra Leone, South Korea, Spain, and Switzerland.
The board included members with relevant biomedical expertise such as past president of the American Association for Clinical Chemistry Susan A. Evans; William Foege, former director of the U.S. Centers for Disease Control and Prevention (CDC); David Helfet, director of the Orthopedic Trauma Service at the Hospital for Special Surgery; and professors Ann M. Gronowski, Larry J. Kricka, Jack Ladenson, Andy O. Miller and Steven Spitalnik. Balwani left his position as president and COO in May 2016. At that time, the company announced its new board members, Fabrizio Bonanni (former executive vice president of Amgen), Richard Kovacevich and William Foege, who would help to publicly introduce its technologies. In May 2016, members of the Theranos board of directors were:
== Medical uses == Brief reactive psychosis and hypochondriasis-senestopathic syndrome Vegetative dysfunction and vegetative lability Alcohol withdrawal syndrome Temporal lobe epilepsy and myoclonic epilepsy (used only occasionally as better options exist) Hyperkinesia and tics Muscle spasticity Usually, a course of treatment with phenazepam should not normally exceed 2 weeks (in some cases therapy may be prolonged for up to 2 months) due to the risk of drug abuse and dependence. To prevent withdrawal syndrome, it is necessary to reduce the dose gradually.
IC50 / pIC50 values represent binding affinity only and do not reflect efficacy or pharmacokinetics, and some compounds listed are GABAA antagonists rather than agonists (e.g. flumazenil). Low IC50 or high pIC50 values indicate tighter binding (pIC50 of 8.0 = IC50 of 10nM, pIC50 of 9.0 = IC50 of 1nM, etc.) These are non subtype selective IC50 values averaged across all GABAA receptor subtypes, so subtype selective compounds with strong binding at one subtype but weak at others will appear unusually weak due to averaging of binding values (see e.g. CL-218,872) † indicates a predicted value from in silico modelling. Finally, note that the benzodiazepine core is a privileged scaffold, which has been used to derive drugs with diverse activity that is not limited to the GABAA modulatory action of the classical benzodiazepines, such as devazepide and tifluadom, however these have not been included in the list below. 2,3-benzodiazepines such as tofisopam are also not listed, as these act primarily as AMPA receptor modulators, and are inactive at GABAA receptors.
Sources: en.wikipedia.org
In response to a systemic bacterial infection, the immune system initiates a process known as iron withholding. If bacteria are to survive, then they must obtain iron from their environment. Disease-causing bacteria do this in many ways, including releasing iron-binding molecules called siderophores and then reabsorbing them to recover iron, or scavenging iron from hemoglobin and transferrin. The harder the bacteria have to work to get iron, the greater a metabolic price they must pay. That means that iron-deprived bacteria reproduce more slowly. So, control of iron levels appears to be an important defense against many bacterial infections. Certain bacteria species have developed strategies to circumvent that defense, TB causing bacteria can reside within macrophages, which present an iron-rich environment and Borrelia burgdorferi uses manganese in place of iron. People with increased amounts of iron, as, for example, in hemochromatosis, are more susceptible to some bacterial infections. Although this mechanism is an elegant response to short-term bacterial infection, it can cause problems when it goes on so long that the body is deprived of needed iron for red cell production. Inflammatory cytokines stimulate the liver to produce the iron metabolism regulator protein hepcidin, that reduces available iron. If hepcidin levels increase because of non-bacterial sources of inflammation, like viral infection, cancer, auto-immune diseases or other chronic diseases, then the anemia of chronic disease may result.
Every mission demonstrated the ability to adjust the crafts' inclination and apsis without issue. Gemini 5 demonstrated eight-day endurance, long enough for a round trip to the Moon. Gemini 7 demonstrated a fourteen-day endurance flight. Gemini 6A demonstrated rendezvous and station-keeping with Gemini 7 for three consecutive orbits at distances as close as 1 foot (0.30 m). Gemini 9A also achieved rendezvous with an Agena Target Vehicle (ATV). Rendezvous and docking with the ATV was achieved on Gemini 8, 10, 11, and 12. Gemini 11 achieved the first direct-ascent rendezvous with its Agena target on the first orbit. Extravehicular activity (EVA) was perfected through increasing practice on Gemini 4, 9A, 10, 11, and 12. On Gemini 12, Edwin "Buzz" Aldrin spent over five hours working comfortably during three (EVA) sessions, finally proving that humans could perform productive tasks outside their spacecraft. Gemini 10, 11, and 12 used the ATV's engine to make large changes in its orbit while docked. Gemini 11 used the Agena's rocket to achieve a crewed Earth orbit record apogee of 742 nautical miles (1,374 km). Gemini 8 experienced the first in-space mission abort on March 17, 1966, just after achieving the world's first docking, when a stuck or shorted thruster sent the craft into an uncontrolled spin. Command pilot Neil Armstrong was able to shut off the stuck thruster and stop the spin by using the re-entry control system. He and his crewmate David Scott landed and were recovered safely. Most of the novice pilots on the early missions would command the later missions.
According to the 2025 Global Organized Crime Index, Pakistan had a criminality score of 6.32 out of 10, ranking 45th among 193 countries, and a resilience score ranking 131st among 193 countries, with the latter measuring the country's capacity to withstand and respond to organized crime. According to the Federal Investigation Agency's annual report, the agency received more than 73,000 cybercrime complaints in 2024, of which 1,604 were registered as cases, with financial fraud accounting for nearly half of all complaints. In 2025, the National Cyber Crimes Investigation Agency estimated that cybercrime had increased by about 35% compared with the previous year. A 2025 survey conducted on behalf of Visa Inc. found that 55% of respondents in Pakistan had fallen victim to an online scam in 2024, while 20% reported having been victims more than once. Pakistan scored 27 out of 100 on the Corruption Perceptions Index in 2024, ranking 135th out of 180 countries in the assessment of perceived public-sector corruption.
Sources: en.wikipedia.org
==== Serbian ==== First Serbian Benevolent Society - The First Serbian Benevolent Society of San Francisco is the oldest Serbian organization in America. Founded in 1880, the FSBS was originally called the Serbian-Montenegrin Literary and Benevolent Society. It was organized to promote social and intellectual interchange, and establish a system of general philanthropy and benevolence for Serbian immigrant laborers toiling far from their homeland. The eight founding members were Antonije Vukasovich, Jovan Jovovich, Jovan Pavkovich, Krsto Gopcevich, Rade Begovich and Vladimir Jovovich, all from Boka Kotorska, George S. Martinovich from Montenegro, and Mikhail Rashkovich from Vojvodina. The Society, which has recently celebrated its 135th anniversary, is headquartered in Colma, CA where it maintains a Serbian Cultural Center and Museum along with a Serbian Cemetery and the Chapel of the Assumption of the Virgin Mary. Serb National Federation - Created after the merger of several Serbian American organizations in 1929. Headquarters in Pittsburgh. Membership open to people of Serb or Slav descent 16–60. Those under 16 can join "Junior Order". In 1979 it had 20,000 members, and "membership groups" existed in 10 states and Canada. In 1995 it had 15,200 members. Sponsors social gatherings, cultural events, sports programs, finances church buildings, and meeting halls.
== Selected publications == Viswanathan, V.; Mirshad, R. (2023), "Role of Technology for wound Care in Diabetic Foot", Chronic Wound Management, Cham: Springer International Publishing, pp. 67–76, doi:10.1007/978-3-031-26110-7_4, ISBN 978-3-031-26109-1 Viswanathan, Vijay; Ahmed Khan, Balkhiwala; Nachimuthu, Sukanya; Kumpatla, Satyavani (2023). "Precision of Michigan Neuropathy Screening Instrument (MNSI) Tool for the Diagnosis of Diabetic Peripheral Neuropathy Among People with Type 2 Diabetes—A Study from South India". The International Journal of Lower Extremity Wounds. doi:10.1177/15347346231163209. ISSN 1534-7346. "Current and future perspective in the management of diabetes". {{cite journal}}: Cite journal requires |journal= (help) "Type 2 Diabetes Mellitus – The Epidemic Of The 21st Century: The Indian Scenario A Ramachandran, C Snehalatha*, Int. J. Diab. Dev. Countries (1999), Vol. 19". {{cite journal}}: Cite journal requires |journal= (help) High Prevalence of Obstructive Sleep Apnea among People with Type 2 Diabetes Mellitus in a Tertiary Care Center. J Assoc Physicians India. 2017 Nov;65(11):38-42. PMID 29322708. Need for education on footcare in diabetic patients in India. J Assoc Physicians India. 1999 Nov;47(11):1083-5. PMID 10862318. Diabetic nephropathy in type 2 diabetes: the Indian experience. J Assoc Physicians India. 2001 Dec;49:1185-7. PMID 11996441. Prevalence of pathogens in diabetic foot infection in South Indian type 2 diabetic patients. J Assoc Physicians India. 2002 Aug;50:1013-6. PMID 12421021.
== References == Church, I.J. & Parsons, A.L.: (1995) Modified Atmosphere Packaging Technology: A Review, Journal Science Food Agriculture, 67, 143-152 Day, B.P.F.: (1996) A perspective of modified atmosphere packaging of fresh produce In Western Europe, Food Science and Technology Today, 4,215-221 European Food Information Council (EFIC: (2001) Opinion of the Scientific Committee on Food on the use of carbon monoxide as component of packaging gases in modified atmosphere packaging for fresh meat. Parry, R. T.: (1993) Principles and applications of MAP of foods, Blackie Academic & Professional, England, 1-132 Phillips, C.A.: (1996) Review: Modified Atmosphere Packaging and its effects on the microbial quality and safety of produce, International Journal of Food Science and Tech, 31, 463-479 Robertson, G. L., "Food Packaging: Principles and Practice", 3rd edition, 2013, ISBN 978-1-4398-6241-4 Zagory, D. & Kader, A.A.: (1988) Modified atmosphere packaging of fresh produce, Food Technology., 42(9), 70-77
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.